Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma
- PMID: 27931131
- DOI: 10.1080/10428194.2016.1219900
Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma
Abstract
The prothrombotic risk in multiple myeloma (MM) could be potentially assessed by thrombin generation (TG) assays. TG was performed using Calibrated Automated Thrombography with 5 and 1 pM tissue factor. We compared baseline TG among 24 MM patients, 19 MGUS, and 50 healthy controls, and assessed change in TG in MM patients during the initial treatment period at 1, 2, and 3 months. MM subjects demonstrated increased FVIII and VWF:Ag levels pretreatment, and a prothrombotic TG phenotype with increased velocity index, reduced lag time and time-to-peak, and increased resistance to thrombomodulin inhibition. There were no significant changes in TG with treatment for the majority of parameters, however, MM subjects exhibited persistent elevation of velocity index throughout treatment. Two subjects developed thrombosis during the study period despite thromboprophylaxis. This study provides information on the optimal conditions for examining TG as a predictor of thrombotic risk in MM patients.
Keywords: Monoclonal gammopathy; hypercoagulability; multiple myeloma; thrombin generation; venous thromboembolism.
Similar articles
-
Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy.J Thromb Thrombolysis. 2025 Mar;58(3):467-480. doi: 10.1007/s11239-025-03079-1. Epub 2025 Mar 10. J Thromb Thrombolysis. 2025. PMID: 40064842
-
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.Clin Appl Thromb Hemost. 2016 Sep;22(6):554-62. doi: 10.1177/1076029615625825. Epub 2016 Jan 11. Clin Appl Thromb Hemost. 2016. PMID: 26759370
-
Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated protein C.Thromb Res. 2023 Mar;223:44-52. doi: 10.1016/j.thromres.2023.01.010. Epub 2023 Jan 23. Thromb Res. 2023. PMID: 36708689
-
Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.Semin Hematol. 2011 Jan;48(1):46-54. doi: 10.1053/j.seminhematol.2010.11.002. Semin Hematol. 2011. PMID: 21232658 Review.
-
Management of newly diagnosed myeloma.Hematol Oncol Clin North Am. 2007 Dec;21(6):1141-56, ix-x. doi: 10.1016/j.hoc.2007.08.008. Hematol Oncol Clin North Am. 2007. PMID: 17996592 Review.
Cited by
-
Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma.J Thromb Thrombolysis. 2023 Apr;55(3):464-473. doi: 10.1007/s11239-022-02765-8. Epub 2023 Jan 11. J Thromb Thrombolysis. 2023. PMID: 36630029
-
Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools.Cancers (Basel). 2020 Jan 13;12(1):191. doi: 10.3390/cancers12010191. Cancers (Basel). 2020. PMID: 31940972 Free PMC article. Review.
-
Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy.J Thromb Thrombolysis. 2025 Mar;58(3):467-480. doi: 10.1007/s11239-025-03079-1. Epub 2025 Mar 10. J Thromb Thrombolysis. 2025. PMID: 40064842
-
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.JHEP Rep. 2020 May 11;2(4):100120. doi: 10.1016/j.jhepr.2020.100120. eCollection 2020 Aug. JHEP Rep. 2020. PMID: 32715285 Free PMC article.
-
Thrombin Generation and Cancer: Contributors and Consequences.Cancers (Basel). 2019 Jan 16;11(1):100. doi: 10.3390/cancers11010100. Cancers (Basel). 2019. PMID: 30654498 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous